一种 Guanosine 衍生的抗瘤超分子原药
Shuyun Wang1, Nanrong Hu1, Bo Deng2
1State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, Chaoyang District, Beijing 100029, P.R. China.
Biomacromolecules
|December 8, 2023
概括
这项研究介绍了GB-SN38,一种用于输送化疗药物SN38.8的新型水凝. 它在响应瘤微环境时释放药物,减少全身毒性并改善瘤抑制.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 癌症治疗方法 癌症治疗方法
背景情况:
- 前药物策略增强药物特性,特别是在化疗中.
- 氨酸的活性代谢物SN38具有潜力,但在激活和毒性方面面临挑战.
- 有针对性的药物输送系统对于提高癌症治疗疗效至关重要.
研究的目的:
- 开发一种新型的G-四倍体水凝 (GB-SN38),用于控制释放SN38.
- 为了实现ROS触发的药物释放,绕过了氧化酶激活.
- 为了评估GB-SN38水凝的生物安全性和抗瘤功效.
主要方法:
- 将SN38 (一种酸盐衍生物) 纳入G-四重复合液凝中.
- 使用酸乙烯的氧化水解来释放ROS特异性药物.
- 综合光谱学用于结构和物理化学表征.
- 在体外和体内测试用于安全性和疗效的评估.
主要成果:
- 在GB-SN38水凝成功合成和特征.
- 药物释放是独立于碳酸乙酶的,并由ROS特别触发.
- 在临床前模型中,水凝显示出高生物安全性和显著的瘤抑制特性.
- 由于有针对性的SN38输送,观察到系统性毒性降低.
结论:
- GB-SN38水凝代表了增强癌症治疗的有希望的前药物策略.
- 由ROS触发的释放机制最大限度地减少了与传统SN38输送相关的副作用.
- 这种方法提供了一种更安全,更有效的方法来提供化疗剂.
更多相关视频
08:46Regioselective O-Glycosylation of Nucleosides via the Temporary 2',3'-Diol Protection by a Boronic Ester for the Synthesis of Disaccharide Nucleosides
Published on: July 26, 2018
8.7K
09:45Modification and Functionalization of the Guanidine Group by Tailor-made Precursors
Published on: April 27, 2017
10.7K
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
184
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
184
GTPases and their Regulation
8.4K
Guanine nucleotide-binding proteins (G-proteins), also known as GTPases, are a superfamily of proteins that regulate many cellular processes, such as cell signaling, vesicular transport, and the regulation of cell shape and motility. Mutation or dysfunction of these proteins can lead to disease. There are around 40,000 known G-proteins that can broadly be classified into two groups ‒ small G-proteins consisting of a single domain and large multi-domain G-proteins.
Large G-proteins,...
Large G-proteins,...
8.4K
